髄膜炎菌ワクチン市場レポート：2024-2034
Meningococcal Vaccines Market Report 2024-2034
レポート詳細
髄膜炎菌ワクチン市場レポート 2024-2034年 ：本レポートは、業界とその基礎となる原動力をより良く理解したいと望むなら、新たな収益ポケットを目指す大手企業にとって貴重なものとな... もっと見る
※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。
サマリー
レポート詳細
髄膜炎菌ワクチン市場レポート 2024-2034年：本レポートは、業界とその基礎となる原動力をより良く理解したいと望むなら、新たな収益ポケットを目指す大手企業にとって貴重なものとなるでしょう。異業種への進出や新規地域での既存事業の拡大を目指す企業にも有用です。
R＆Dの難しさ
ワクチンの導入には膨大な研究開発が必要である。R＆Dに影響を与える主な要因には、インフラの不足、限られた資金調達機会、原材料入手の障壁、業務上の不備などがある。さらに、R＆Dコストは、大企業であれば管理可能であるが、中小企業では様々な課題に直面する。また、規制プロセスは複雑で、多くの書類作成やフォローアップを必要とするため、ワクチン研究にはさらに時間がかかる。したがって、研究を強化するためにR＆Dプロセスを合理化する必要がある。
市場調査レポートを購入する前にすべき質問とは？
-
髄膜炎菌ワクチン市場はどのように発展しているのか？
-
何が髄膜炎菌ワクチン市場を牽引し、阻害しているのか？
-
髄膜炎菌ワクチンの各サブマーケットは予測期間中にどのように成長し、2034年にはどれくらいの売上を占めるようになるのか？
-
2024年から2034年にかけて、髄膜炎菌ワクチンの各サブマーケットの市場シェアはどのように推移するのか？
-
2024年から2034年にかけて、市場全体を牽引する主な要因は何か？
-
主要な髄膜炎菌ワクチン市場はマクロ経済の動きに幅広く追随するのか、それとも個々の国の市場が他を凌駕するのか？
-
2034年までに各国市場のシェアはどのように変化し、どの地域が2034年の市場をリードするのか。
-
主要プレーヤーと予測期間中の見通しは？
-
これらの主要企業の髄膜炎菌ワクチンプロジェクトとは？
-
2024年から2034年の間に、業界はどのように発展するのか？髄膜炎菌の影響は？
-
現在、そして今後10年間に実施されるワクチン・プロジェクトは？
-
髄膜炎菌ワクチン市場をさらに拡大するために、製品化の必要性は高まっていますか？
-
髄膜炎菌ワクチン市場はどこへ向かっているのか？
-
新商品や新サービスに最適な投資方法とは？
-
企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？
このことが髄膜炎菌ワクチン市場に現在、そして今後10年間でどのような影響を与えるかを知る必要がある：
-
239ページにわたるレポートでは、105の表、161のグラフとチャートを掲載している。
-
このレポートでは、業界の主要な収益分野に焦点を当てているため、今すぐそこにターゲットを絞ることができます。
-
世界、地域、国の売上高と成長に関する詳細な分析が含まれている。
-
競合他社が成功した主なトレンド、変化、収益予測をハイライトします。
本レポートは、髄膜炎菌ワクチン市場が今後10年間でどのように発展し、COVID-19の景気後退と好転の変動に合わせて発展していくかをお伝えします。この市場は過去10年間のどの時点よりも今が重要です。
2034年までの予測やその他の分析から、商業的な展望が明らかになる
-
2034年までの収益予測に加え、最近の実績、成長率、市場シェアも提供している。
-
ビジネスの展望や展開など、独自の分析が掲載されている。
-
定性的分析（市場力学、促進要因、機会、阻害要因、課題を含む）、コスト構造、髄膜炎菌ワクチン価格上昇の影響、最近の動向をご覧ください。
本レポートには、COVID-19が業界と貴社にどのような影響を与えるかについてのデータ分析と貴重な洞察が含まれている。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じている。
レポート対象セグメント
タイプ
-
多糖類ワクチン
-
結合型ワクチン
-
混合ワクチン
-
メンBワクチン
セログループ
-
A、B、C、Y、W-135ワクチン
-
セログループBワクチン
ブランド
-
メナクトラ
-
メンベオ
-
ニメニックス
-
ベクセロ
-
トルメンバ
流通チャネル
世界市場全体とセグメント別の収益予測に加え、5つの地域と20の主要国市場の収益予測も掲載しています：
北米
欧州
-
ドイツ
-
英国
-
フランス
-
イタリア
-
スペイン
-
その他の欧州
アジア太平洋
-
中国
-
日本
-
インド
-
オーストラリア
-
韓国
-
その他のアジア太平洋
ラテンアメリカ
MEA
本レポートには、髄膜炎菌ワクチン市場の2024年から2034年までの主要企業のプロファイルも含まれており、これらの企業の事業のこのセグメントに焦点を当てている。
報告書に掲載されている主要企業
-
BIO-MED
-
GSK plc
-
Hualan Biological Bacterin Co., Ltd.
-
Incepta Pharmaceuticals Ltd.
-
JN International
-
Pfizer Inc.
-
Sanofi
-
Serum Institute of India Pvt. Ltd.
-
Walvax Biotechnology Co., Ltd.
髄膜炎菌ワクチン市場全体の世界売上高、2024～2034年、金額ベースでは2024年に31億米ドルを突破する、との試算を発表。2034年まで収益は力強く成長すると予測。当社の調査では、どの企業が最も大きな可能性を秘めているかを特定しています。彼らの能力、進歩、商業的展望を発見し、一歩先を行くお手伝いをします。
髄膜炎菌ワクチン市場、2024-2034年レポートはどのように役立ちますか？
要約すると、230ページを超えるこのレポートは、以下のような知識を提供する：
-
髄膜炎菌ワクチン市場、2024年から2034年までの収益予測 世界および地域レベルでのタイプ、血清群、ブランド、流通チャネルの各予測による、髄膜炎菌ワクチン市場の2034年までの収益予測 - 業界の展望を発見し、投資と収益に最も有利な場所を見つけます。
-
5つの地域と20の主要国市場の2034年までの収益予測 - 髄膜炎菌ワクチン市場、北米、欧州、アジア太平洋、ラテンアメリカ、MEAの2024年から2034年までの市場予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなどの主要経済圏の市場も予測しています。
-
2024年から2034年までの髄膜炎菌ワクチン市場に関わる主要企業9社の企業プロファイルを含む。
独自の予測による定量的・定性的分析をご覧ください。私たちのレポートだけに含まれる情報を入手し、貴重なビジネスインテリジェンスで情報を得ることができます。
他にはない情報
私たちの新しいレポートがあれば、知識に遅れをとったり、チャンスを逃したりする可能性が低くなります。Visiongainの調査レポートが貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの調査は、髄膜炎菌ワクチン市場、2024年から2034年、市場をリードする企業の商業分析を必要とするすべての人のためのものです。データ、トレンド、予測をご覧いただけます。
ページTOPに戻る
目次
目次
1.レポート概要
1.1 研究の目的
1.2 髄膜炎菌ワクチン市場の紹介
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問は以下の通りです：
1.6 本レポートは誰のためのものか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.8 よくある質問（FAQ）
1.9 関連レポート
1.10 Visiongainについて
2 エグゼクティブ・サマリー
3 市場概要
3.1 主要な調査結果
3.2 市場ダイナミクス
3.2.1 市場促進要因
3.2.2 市場抑制要因
3.2.3 市場機会
3.3 COVID-19の影響分析
3.4 ポーターのファイブフォース分析
3.4.1 供給者パワー
3.4.2 バイヤーパワー
3.4.3 競争力
3.4.4 代替品の脅威
3.4.5 新規参入企業の脅威
3.5 PEST分析
4 髄膜炎菌ワクチン市場分析：タイプ別
4.1 主な調査結果
4.2 タイプ別セグメント 市場魅力度指数
4.3 髄膜炎菌ワクチンの種類別市場規模推定と予測
4.4 多糖類ワクチン
4.4.1 多糖類ワクチンの地域別市場予測、2024〜2034年（US$ Mn）
4.4.2 多糖類ワクチンの地域別市場シェア、2024・2034年 (%)
4.5 抱合型ワクチン
4.5.1 2024〜2034年、地域別混合ワクチン市場予測（US$ Mn）
4.5.2 抱合型ワクチンの地域別市場シェア、2024・2034年 (%)
4.6 混合ワクチン
4.6.1 混合ワクチンの地域別市場予測、2024-2034年 (US $ Mn)
4.6.2 混合ワクチンの地域別市場シェア、2024・2034年 (%)
4.7 男性B型ワクチン
4.7.1 男性B型ワクチンの地域別市場予測、2024-2034年 (US $ Mn)
4.7.2 男性B型ワクチンの地域別市場シェア、2024・2034年 (%)
5 髄膜炎菌ワクチン市場分析：血清群別
5.1 主要な調査結果
5.2 血清群別セグメント 市場魅力度指数
5.3 血清群別髄膜炎菌ワクチン市場規模推定と予測
5.4 髄膜炎菌ワクチンの血清群別市場シェア、2024年・2034年
5.5 A、B、C、Y、W-135ワクチン
5.5.1 A、B、C、Y、W-135ワクチンの地域別市場予測、2024〜2034年 (US $ Mn)
5.5.2 A、B、C、Y、W-135ワクチンの地域別市場シェア、2024-2034年 (%)
5.6 セログループBワクチン
5.6.1 セログループメンBワクチンの地域別市場予測、2024-2034年 (US $ Mn)
5.6.2 血清群メンBワクチンの地域別市場シェア、2024-2034年 (%)
6 髄膜炎菌ワクチン市場分析：ブランド別
6.1 主要調査結果
6.2 メナクトラ
6.2.1 Menactraの市場予測、2024-2034 (US$ Mn)
6.3 メンベオ
6.3.1 メンベオの市場予測、2024-2034年（US$ Mn）
6.4 ニメンリックス
6.4.1 ニメンリックスの市場予測、2024-2034年（US$ Mn）
6.5 ベクセロ
6.5.1 Bexseroの市場予測、2024～2034年（US$ Mn）
6.6 トルメンバ
6.6.1 Trumenbaの市場予測、2024-2034年（US$ Mn）
7 髄膜炎菌ワクチンの流通経路別市場分析
7.1 主要な調査結果
7.2 流通チャネルセグメント市場魅力度指数
7.3 髄膜炎菌ワクチンの市場規模推計と流通チャネル別予測
7.4 髄膜炎菌ワクチンの流通チャネル別市場シェア（2024年、2029年、2034年
7.5 病院薬局
7.5.1 病院薬局の地域別市場予測、2024-2034年（US$ Mn）
7.5.2 病院薬局の地域別市場シェア、2024-2034年(%)
7.6 小売薬局
7.6.1 小売薬局の地域別市場予測、2024-2034年（US$ Mn）
7.6.2 小売薬局の地域別市場シェア、2024-2034年(%)
7.7 オンライン薬局
7.7.1 オンライン薬局の地域別市場予測、2024-2034年（US$ Mn）
7.7.2 オンライン薬局市場地域別シェア、2024-2034年(%)
8 髄膜炎菌ワクチン市場分析：地域別
8.1 主要な調査結果
8.2 地域別市場規模の推定と予測
9 北米の髄膜炎菌ワクチン市場分析
9.1 主要な調査結果
9.2 北米の髄膜炎菌ワクチン市場魅力度指数
9.3 北米の髄膜炎菌ワクチン国別市場、2024年、2029年、2034年（US$ Mn）
9.4 北米の髄膜炎菌ワクチン国別市場規模推定と予測
9.5 北米の髄膜炎菌ワクチン市場規模推定と予測：タイプ別
9.6 北米の髄膜炎菌ワクチン市場規模推定と予測：血清群別
9.7 北米の髄膜炎菌ワクチン市場規模推定と予測：流通経路別
9.8 米国
9.8.1 米国のタイプ別髄膜炎菌ワクチン市場
9.9 カナダ
9.9.1 カナダのタイプ別髄膜炎菌ワクチン市場
10 欧州の髄膜炎菌ワクチン市場分析
10.1 主要な調査結果
10.2 欧州髄膜炎菌ワクチン市場魅力度指数
10.3 欧州の髄膜炎菌ワクチン国別市場：2024年、2029年、2034年（US$ Mn）
10.4 欧州の髄膜炎菌ワクチン市場規模推定と予測：国別
10.5 欧州の髄膜炎菌ワクチン市場規模推定と予測：タイプ別
10.6 欧州の髄膜炎菌ワクチン市場規模推定と予測：血清群別
10.7 欧州の髄膜炎菌ワクチン市場規模推定と予測：流通経路別
10.8 ドイツ
10.8.1 ドイツのタイプ別髄膜炎菌ワクチン市場
10.9 イギリス
10.9.1 イギリスのタイプ別髄膜炎菌ワクチン市場
10.10 フランス
10.10.1 フランスのタイプ別髄膜炎菌ワクチン市場
10.11 イタリア
10.11.1 タイプ別イタリア髄膜炎菌ワクチン市場
10.12 スペイン
10.12.1 スペインのタイプ別髄膜炎菌ワクチン市場
10.13 その他の地域
10.13.1 その他の欧州のタイプ別髄膜炎菌ワクチン市場
11 アジア太平洋地域の髄膜炎菌ワクチン市場分析
11.1 主要な調査結果
11.2 アジア太平洋地域の髄膜炎菌ワクチン市場魅力度指数
11.3 アジア太平洋地域の髄膜炎菌ワクチン市場国別、2024年、2029年、2034年（US$ Mn）
11.4 アジア太平洋地域の髄膜炎菌ワクチン市場規模推定と予測：国別
11.5 アジア太平洋地域の髄膜炎菌ワクチン市場規模推定と予測：タイプ別
11.6 アジア太平洋地域の髄膜炎菌ワクチン市場規模推定と予測：血清群別
11.7 アジア太平洋地域の髄膜炎菌ワクチン市場規模推定と予測：流通経路別
11.8 日本
11.9 中国
11.9.1 中国のタイプ別髄膜炎菌ワクチン市場
11.10 インド
11.10.1 インドのタイプ別髄膜炎菌ワクチン市場
11.11 韓国
11.11.1 韓国のタイプ別髄膜炎菌ワクチン市場
11.12 オーストラリア
11.12.1 オーストラリアのタイプ別髄膜炎菌ワクチン市場
11.13 その他の地域
11.13.1 その他の地域のタイプ別髄膜炎菌ワクチン市場
12 ラテンアメリカ髄膜炎菌ワクチン市場分析
12.1 主な調査結果
12.2 ラテンアメリカの髄膜炎菌ワクチン市場魅力度指数
12.3 ラテンアメリカの髄膜炎菌ワクチン国別市場、2024年、2029年、2034年（US$ Mn）
12.4 ラテンアメリカの髄膜炎菌ワクチン市場規模推定と予測：国別
12.5 ラテンアメリカの髄膜炎菌ワクチン市場規模推定と予測：タイプ別
12.6 ラテンアメリカの髄膜炎菌ワクチン市場規模推定と予測：血清群別
12.7 ラテンアメリカの髄膜炎菌ワクチン市場規模推定と予測：流通経路別
12.8 ブラジル
12.8.1 ブラジルのタイプ別髄膜炎菌ワクチン市場
12.9 メキシコ
12.10 その他のラテンアメリカ
12.10.1 その他のラテンアメリカのタイプ別髄膜炎菌ワクチン市場
13 MEAの髄膜炎菌ワクチン市場分析
13.1 主要な調査結果
13.2 MEAの髄膜炎菌ワクチン市場魅力度指数
13.3 MEAの髄膜炎菌ワクチンの国別市場：2024年、2029年、2034年（US$ Mn）
13.4 MEAの髄膜炎菌ワクチン市場規模推定と予測：国別
13.5 MEAの髄膜炎菌ワクチン市場規模推定と予測：タイプ別
13.6 MEAの髄膜炎菌ワクチン市場規模推定と予測：血清群別
13.7 MEAの髄膜炎菌ワクチン市場規模推定と予測：流通経路別
13.8 南アフリカ
13.8.1 南アフリカのタイプ別髄膜炎菌ワクチン市場
13.9 GCC
13.9.1 GCCのタイプ別髄膜炎菌ワクチン市場
13.10 その他のMEA
13.10.1 MEAのその他の地域タイプ別髄膜炎菌ワクチン市場
14 競争環境
14.1 企業の市場シェア分析
14.2 主要事業戦略分析
15 会社概要
15.1 GSK plc
15.1.1 会社概要
15.1.2 会社概要
15.1.3 財務分析
15.1.4 製品ベンチマーク
15.1.5 パイプライン分析
15.1.6 戦略的展望
15.2 BIO-MED
15.2.1 会社概要
15.2.2 会社概要
15.2.3 製品ベンチマーク
15.3 Hualan Biological Bacterin Co., Ltd.
15.3.1 会社概要
15.3.2 会社概要
15.3.3 製品ベンチマーク
15.4 Incepta Pharmaceuticals Ltd.
15.4.1 会社概要
15.4.2 会社概要
15.4.3 製品ベンチマーク
15.5 JN International
15.5.1 会社概要
15.5.2 会社概要
15.5.3 製品ベンチマーク
15.6 Pfizer Inc.
15.6.1 会社概要
15.6.2 会社概要
15.6.3 財務分析
15.6.4 製品ベンチマーク
15.6.5 戦略的展望
15.7 Sanofi
15.7.1 会社概要
15.7.2 会社概要
15.7.3 財務分析
15.7.4 製品ベンチマーク
15.7.5 パイプライン分析
15.7.6 戦略的展望
15.8 Serum Institute of India Pvt.
15.8.1 会社概要
15.8.2 会社概要
15.8.3 製品ベンチマーク
15.8.4 戦略的展望
15.9 Walvax Biotechnology Co.
15.9.1 会社概要
15.9.2 会社概要
15.9.3 製品ベンチマーク
15.9.4 パイプライン分析
16 結論と提言
16.1 Visiongainの結論
16.2 市場プレイヤーへの提言
ページTOPに戻る
図表リスト
表の一覧
Table 1 Meningococcal Vaccines Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
Table 2 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (V-shaped Recovery)
Table 3 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (U-shaped Recovery)
Table 4 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (W-shaped Recovery)
Table 5 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (L-shaped Recovery)
Table 6 Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 7 Polysaccharide Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 8 Conjugate Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 9 Combination Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 10 Men B Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 11 Meningococcal Vaccines Market by Serogroups, By Type 2024-2034 (US$ Million, AGR %, CAGR %)
Table 12 A, B, C, Y, W-135 Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 13 Men B Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 14 Menactra Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 15 Menveo Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 16 Nimenrix Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 17 Bexsero Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 18 Trumenba Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 19 Meningococcal Vaccines Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 20 Hospital Pharmacies Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 21 Retail Pharmacies Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 22 Online Pharmacies Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 23 Meningococcal Vaccines Market, By Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 24 North America Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 25 North America Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 26 North America Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 27 North America Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 28 U.S. Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 29 U.S. Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 30 Canada Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 31 Canada Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 32 Europe Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 33 Europe Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 34 Europe Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 35 Europe Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 36 Germany Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 37 Germany Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 38 U.K. Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 39 UK Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 40 France Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 41 France Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 42 Italy Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 43 Italy Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 44 Spain Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 45 Spain Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 46 Rest of Europe Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 47 Rest of Europe Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 48 Asia Pacific Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 49 Asia Pacific Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 50 Asia Pacific Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 51 Asia Pacific Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 52 China Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 53 China Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 54 India Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 55 India Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 56 South Korea Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 57 South Korea Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 58 Australia Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 59 Australia Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 60 Rest of Asia Pacific Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 61 Rest of Asia Pacific Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 62 Latin America Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 63 Latin America Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 64 Latin America Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 65 Latin America Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 66 Brazil Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 67 Brazil Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 68 Rest of LATAM Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 69 Rest of LATAM Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 70 MEA Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 71 MEA Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 72 MEA Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 73 MEA Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 74 South Africa Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 75 South Africa Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 76 GCC Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 77 GCC Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 78 Rest of MEA Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 79 Rest of MEA Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 80 Key Business Strategies Adopted by Key Players in Meningococcal Vaccines Market Details
Table 81 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 GSK plc: Product Benchmarking
Table 83 GSK plc: Product Pipeline
Table 84 GSK plc: Company Recent Developments
Table 85 BIO-MED: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 BIO-MED: Product Benchmarking
Table 87 Hualan Biological Bacterin Co., Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Hualan Biological Bacterin Co., Ltd: Product Benchmarking
Table 89 Incepta Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Incepta Pharmaceuticals Ltd.: Product Benchmarking
Table 91 JN International: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 JN International: Product Benchmarking
Table 93 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Pfizer Inc.: Product Benchmarking
Table 95 Pfizer Inc.: Company Recent Developments
Table 96 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Sanofi: Product Benchmarking
Table 98 Sanofi: Product Pipeline
Table 99 Sanofi: Company Recent Developments
Table 100 Serum Institute of India Pvt. Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Serum Institute of India Pvt. Ltd: Product Benchmarking
Table 102 Serum Institute of India Pvt. Ltd: Company Recent Developments
Table 103 Walvax Biotechnology Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Walvax Biotechnology Co., Ltd.: Product Benchmarking
Table 105 Walvax Biotechnology Co., Ltd.: Product Pipeline
図の一覧
Figure 1 Meningococcal Vaccines Market Segmentation
Figure 2 Meningococcal Vaccines Market Forecast by Region: Market Attractiveness Index
Figure 3 Meningococcal Vaccines Market by Type: Market Attractiveness Index
Figure 4 Meningococcal Vaccines Market by Serogroups: Market Attractiveness Index
Figure 5 Meningococcal Vaccines Market by Distribution Channel: Market Attractiveness Index
Figure 6 Meningococcal Vaccines Market: Market Dynamics
Figure 7 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): “V” Shaped Recovery
Figure 8 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): “U” Shaped Recovery
Figure 9 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): “W” Shaped Recovery
Figure 10 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): “L” Shaped Recovery
Figure 11 Meningococcal Vaccines Market: Porter’s Five Forces Analysis
Figure 12 Meningococcal Vaccines Market: PEST Analysis
Figure 13 Meningococcal Vaccines Market Forecast by Type 2023 (Revenue, CAGR%)
Figure 14 Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 15 Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 16 Polysaccharide Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 17 Polysaccharide vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 18 Conjugate Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 19 Conjugate vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 20 Combination Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 21 Combination Vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 22 Men B Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 23 Men B vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 24 Meningococcal Vaccines Market Forecast by Serogroups 2023 (Revenue, CAGR%)
Figure 25 Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 26 Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 27 A, B, C, Y, W-135 Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 28 A, B, C, Y, W-135 vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 29 Serogroup Men B Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 30 Serogroup Men B Vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 31 Menactra Market Forecast, 2024-2034 (US$ million)
Figure 32 Menveo Market Forecast, 2024-2034 (US$ million)
Figure 33 Nimenrix Market Forecast, 2024-2034 (US$ million)
Figure 34 Bexsero Market Forecast, 2024-2034 (US$ million)
Figure 35 Trumenba Market Forecast, 2024-2034 (US$ million)
Figure 36 Meningococcal Vaccines Market Forecast by Distribution Channel 2023 (Revenue, CAGR%)
Figure 37 Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 38 Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 39 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 40 Hospital Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 41 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 42 Retail Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 43 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 44 Online Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 45 Meningococcal Vaccines Market Forecast by Region 2024, 2034 (Revenue)
Figure 46 Meningococcal Vaccines Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 47 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Figure 48 North America Meningococcal Vaccines Market Attractiveness Index
Figure 49 North America Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 50 North America Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 51 North America Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034(%)
Figure 52 North America Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 53 North America Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 54 North America Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 55 North America Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 56 North America Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 57 North America Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 58 U.S. Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 59 U.S. Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 60 U.S. Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 61 Canada Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 62 Canada Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 63 Canada Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 64 Europe Meningococcal Vaccines Market Attractiveness Index
Figure 65 Europe Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 66 Europe Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 67 Europe Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 68 Europe Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 69 Europe Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 70 Europe Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 71 Europe Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 72 Europe Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 73 Europe Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 74 Germany Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 75 Germany Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 76 Germany Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 77 UK Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 78 U.K. Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 79 U.K. Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 80 France Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 81 France Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 82 France Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 83 Italy Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 84 Italy Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 85 Italy Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 86 Spain Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 87 Spain Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 88 Spain Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 89 Rest of Europe Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 90 Rest of Europe Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 91 Rest of Europe Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 92 Asia Pacific Meningococcal Vaccines Market Attractiveness Index
Figure 93 Asia Pacific Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 94 Asia Pacific Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 95 Asia Pacific Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 96 Asia Pacific Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 97 Asia Pacific Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 98 Asia Pacific Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 99 Asia Pacific Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 100 Asia Pacific Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 101 Asia Pacific Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 102 China Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 103 China Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 104 China Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 105 India Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 106 India Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 107 India Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 108 South Korea Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 109 South Korea Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 110 South Korea Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 111 Australia Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 112 Australia Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 113 Australia Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 114 Rest of Asia Pacific Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 115 Rest of APAC Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 116 Rest of APAC Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 117 Latin America Meningococcal Vaccines Market Attractiveness Index
Figure 118 Latin America Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 119 Latin America Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 120 Latin America Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 121 Latin America Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 122 Latin America Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 123 Latin America Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 124 Latin America Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 125 Latin America Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 126 Latin America Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 127 Brazil Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 128 Brazil Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 129 Brazil Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 130 Rest of LATAM Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 131 Rest of LATAM Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 132 Rest of LATAM Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 133 MEA Meningococcal Vaccines Market Attractiveness Index
Figure 134 MEA Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 135 MEA Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 136 MEA Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 137 MEA Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 138 MEA Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 139 MEA Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 140 MEA Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 141 MEA Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 142 MEA Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 143 South Africa Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 144 South Africa Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 145 South Africa Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 146 GCC Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 147 GCC Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 148 GCC Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 149 Rest of MEA Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 150 Rest of MEA Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 151 Rest of MEA Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 152 Meningococcal Vaccines Market: Company Market Share Analysis, 2022
Figure 153 GSK plc: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 154 GSK plc: Regional Market Shares, 2022
Figure 155 GSK plc: R&D, 2018-2022 (US$ Million, AGR %)
Figure 156 Pfizer Inc.: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 157 Pfizer Inc.: Regional Market Shares, 2022
Figure 158 Pfizer Inc.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 159 Sanofi: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 160 Sanofi: Regional Market Shares, 2022
Figure 161 Sanofi: R&D, 2018-2022 (US$ Million, AGR %)
ページTOPに戻る
Summary
Report Details
The Meningococcal Vaccines Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Difficulties in R&D
Introduction of vaccine requires immense amount of research and development. Key factors that impact R&D include lack of infrastructure, limited funding opportunities, barriers to obtaining raw material, operational insufficiencies. Furthermore, R&D costs can be manageable for large dominant players while small players face various. challenges. Also, regulatory processes are complex and require lot of documentation and follow-up that further adds to time consuming process for vaccine research. Hence, there is a need to streamline R&D process for enhancing research.
What Questions Should You Ask before Buying a Market Research Report?
-
How is the Meningococcal Vaccines market evolving?
-
What is driving and restraining the Meningococcal Vaccines market?
-
How will each Meningococcal Vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
-
How will the market shares for each Meningococcal Vaccines submarket develop from 2024 to 2034?
-
What will be the main driver for the overall market from 2024 to 2034?
-
Will leading Meningococcal Vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
-
How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
-
Who are the leading players and what are their prospects over the forecast period?
-
What are the Meningococcal Vaccines projects for these leading companies?
-
How will the industry evolve during the period between 2024 and 2034? What are the implications of Meningococcal
-
Vaccines projects taking place now and over the next 10 years?
-
Is there a greater need for product commercialisation to further scale the Meningococcal Vaccines market?
-
Where is the Meningococcal Vaccines market heading and how can you ensure you are at the forefront of the market?
-
What are the best investment options for new product and service lines?
-
What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Meningococcal Vaccines market today, and over the next 10 years:
-
Our 239-page report provides 105 tables, 161 charts and graphs exclusively to you.
-
The report highlights key lucrative areas in the industry so you can target them – NOW.
-
It contains in-depth analysis of global, regional and national sales and growth.
-
It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Meningococcal Vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
-
In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
-
You will find original analyses, with business outlooks and developments.
-
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Meningococcal Vaccines prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Type
-
Polysaccharide Vaccines
-
Conjugate Vaccines
-
Combination Vaccines
-
Men B Vaccines
Serogroups
-
A, B, C, Y, W-135 Vaccines
-
Serogroup B Vaccines
Brands
-
Menactra
-
Menveo
-
Nimenrix
-
Bexsero
-
Trumenba
Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:
North America
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Rest of Europe
Asia Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Rest of Asia Pacific
Latin America
-
Brazil
-
Mexico
-
Rest of Latin America
MEA
-
GCC
-
South Africa
-
Rest of MEA
The report also includes profiles and for some of the leading companies in the Meningococcal Vaccines Market, 2024 to 2034, with a focus on this segment of these companies’ operations.
Leading companies profiled in the report
-
BIO-MED
-
GSK plc
-
Hualan Biological Bacterin Co., Ltd.
-
Incepta Pharmaceuticals Ltd.
-
JN International
-
Pfizer Inc.
-
Sanofi
-
Serum Institute of India Pvt. Ltd.
-
Walvax Biotechnology Co., Ltd.
Overall world revenue for Meningococcal Vaccines Market, 2024 to 2034 in terms of value the market will surpass US$3,100.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Meningococcal Vaccines Market, 2024 to 2034 report help you?
In summary, our 230+ page report provides you with the following knowledge:
-
Revenue forecasts to 2034 for Meningococcal Vaccines Market, 2024 to 2034 Market, with forecasts for type, serogroups, brands, and distribution channel each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
-
Revenue forecasts to 2034 for five regional and 20 key national markets – See forecasts for the Meningococcal Vaccines Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, U.K., Italy, China, India, Japan, and Australia among other prominent economies.
-
Prospects for established firms and those seeking to enter the market – including company profiles for 9 of the major companies involved in the Meningococcal Vaccines Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Meningococcal Vaccines Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
ページTOPに戻る
Table of Contents
Table of Contents
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Meningococcal Vaccines Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.2 Market Restraining Factors
3.2.3 Market Opportunities
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat of Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Meningococcal Vaccines Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Meningococcal Vaccines Market Size Estimation and Forecast by Type
4.4 Polysaccharide vaccines
4.4.1 Polysaccharide Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
4.4.2 Polysaccharide vaccines Market Share by Region, 2024-2034 (%)
4.5 Conjugate vaccines
4.5.1 Conjugate Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
4.5.2 Conjugate vaccines Market Share by Region, 2024-2034 (%)
4.6 Combination vaccines
4.6.1 Combination Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
4.6.2 Combination Vaccines Market Share by Region, 2024-2034 (%)
4.7 Men B vaccines
4.7.1 Men B Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
4.7.2 Men B vaccines Market Share by Region, 2024-2034 (%)
5 Meningococcal Vaccines Market Analysis by Serogroups
5.1 Key Findings
5.2 Serogroups Segment: Market Attractiveness Index
5.3 Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
5.4 Meningococcal Vaccines Market Share by Serogroups, 2024 & 2034
5.5 A, B, C, Y, W-135 vaccines
5.5.1 A, B, C, Y, W-135 Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
5.5.2 A, B, C, Y, W-135 vaccines Market Share by Region, 2024-2034 (%)
5.6 Serogroup B vaccines
5.6.1 Serogroup Men B Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
5.6.2 Serogroup Men B Vaccines Market Share by Region, 2024-2034 (%)
6 Meningococcal Vaccines Market Analysis by Brand
6.1 Key Findings
6.2 Menactra
6.2.1 Menactra Market Forecast, 2024-2034 (US$ Mn)
6.3 Menveo
6.3.1 Menveo Market Forecast, 2024-2034 (US$ Mn)
6.4 Nimenrix
6.4.1 Nimenrix Market Forecast, 2024-2034 (US$ Mn)
6.5 Bexsero
6.5.1 Bexsero Market Forecast, 2024-2034 (US$ Mn)
6.6 Trumenba
6.6.1 Trumenba Market Forecast, 2024-2034 (US$ Mn)
7 Meningococcal Vaccines Market Analysis by Distribution Channel
7.1 Key Findings
7.2 Distribution Channel Segment: Market Attractiveness Index
7.3 Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
7.4 Meningococcal Vaccines Market Share by Distribution Channel, 2024, 2029, 2034
7.5 Hospital Pharmacies
7.5.1 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
7.5.2 Hospital Pharmacies Market Share by Region, 2024-2034 (%)
7.6 Retail Pharmacies
7.6.1 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
7.6.2 Retail Pharmacies Market Share by Region, 2024-2034 (%)
7.7 Online Pharmacies
7.7.1 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
7.7.2 Online Pharmacies Market Share by Region, 2024-2034 (%)
8 Meningococcal Vaccines Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Meningococcal Vaccines Market Analysis
9.1 Key Findings
9.2 North America Meningococcal Vaccines Market Attractiveness Index
9.3 North America Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
9.4 North America Meningococcal Vaccines Market Size Estimation and Forecast by Country
9.5 North America Meningococcal Vaccines Market Size Estimation and Forecast by Type
9.6 North America Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
9.7 North America Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
9.8 U.S.
9.8.1 U.S. Meningococcal Vaccines Market by Type
9.9 Canada
9.9.1 Canada Meningococcal Vaccines Market by Type
10 Europe Meningococcal Vaccines Market Analysis
10.1 Key Findings
10.2 Europe Meningococcal Vaccines Market Attractiveness Index
10.3 Europe Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
10.4 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Country
10.5 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Type
10.6 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
10.7 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
10.8 Germany
10.8.1 Germany Meningococcal Vaccines Market by Type
10.9 U.K.
10.9.1 U.K. Meningococcal Vaccines Market by Type
10.10 France
10.10.1 France Meningococcal Vaccines Market by Type
10.11 Italy
10.11.1 Italy Meningococcal Vaccines Market by Type
10.12 Spain
10.12.1 Spain Meningococcal Vaccines Market by Type
10.13 Rest of Europe
10.13.1 Rest of Europe Meningococcal Vaccines Market by Type
11 Asia Pacific Meningococcal Vaccines Market Analysis
11.1 Key Findings
11.2 Asia Pacific Meningococcal Vaccines Market Attractiveness Index
11.3 Asia Pacific Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
11.4 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Country
11.5 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Type
11.6 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
11.7 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
11.8 Japan
11.9 China
11.9.1 China Meningococcal Vaccines Market by Type
11.10 India
11.10.1 India Meningococcal Vaccines Market by Type
11.11 South Korea
11.11.1 South Korea Meningococcal Vaccines Market by Type
11.12 Australia
11.12.1 Australia Meningococcal Vaccines Market by Type
11.13 Rest of APAC
11.13.1 Rest of APAC Meningococcal Vaccines Market by Type
12 Latin America Meningococcal Vaccines Market Analysis
12.1 Key Findings
12.2 Latin America Meningococcal Vaccines Market Attractiveness Index
12.3 Latin America Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
12.4 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Country
12.5 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Type
12.6 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
12.7 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
12.8 Brazil
12.8.1 Brazil Meningococcal Vaccines Market by Type
12.9 Mexico
12.10 Rest of Latin America
12.10.1 Rest of LATAM Meningococcal Vaccines Market by Type
13 MEA Meningococcal Vaccines Market Analysis
13.1 Key Findings
13.2 MEA Meningococcal Vaccines Market Attractiveness Index
13.3 MEA Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
13.4 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Country
13.5 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Type
13.6 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
13.7 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
13.8 South Africa
13.8.1 South Africa Meningococcal Vaccines Market by Type
13.9 GCC
13.9.1 GCC Meningococcal Vaccines Market by Type
13.10 Rest of MEA
13.10.1 Rest of MEA Meningococcal Vaccines Market by Type
14 Competitive Landscape
14.1 Company Market Share Analysis
14.2 Key Business Strategy Analysis
15 Company Profiles
15.1 GSK plc
15.1.1 Company Snapshot
15.1.2 Company Overview
15.1.3 Financial Analysis
15.1.4 Product Benchmarking
15.1.5 Pipeline Analysis
15.1.6 Strategic Outlook
15.2 BIO-MED
15.2.1 Company Snapshot
15.2.2 Company Overview
15.2.3 Product Benchmarking
15.3 Hualan Biological Bacterin Co., Ltd.
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Product Benchmarking
15.4 Incepta Pharmaceuticals Ltd.
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Product Benchmarking
15.5 JN International
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Product Benchmarking
15.6 Pfizer Inc.
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 Sanofi
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.4 Product Benchmarking
15.7.5 Pipeline Analysis
15.7.6 Strategic Outlook
15.8 Serum Institute of India Pvt. Ltd
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Product Benchmarking
15.8.4 Strategic Outlook
15.9 Walvax Biotechnology Co., Ltd.
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Product Benchmarking
15.9.4 Pipeline Analysis
16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players
ページTOPに戻る
List of Tables/Graphs
List of Tables
Table 1 Meningococcal Vaccines Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
Table 2 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (V-shaped Recovery)
Table 3 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (U-shaped Recovery)
Table 4 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (W-shaped Recovery)
Table 5 Meningococcal Vaccine Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (L-shaped Recovery)
Table 6 Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 7 Polysaccharide Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 8 Conjugate Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 9 Combination Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 10 Men B Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 11 Meningococcal Vaccines Market by Serogroups, By Type 2024-2034 (US$ Million, AGR %, CAGR %)
Table 12 A, B, C, Y, W-135 Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 13 Men B Vaccines Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 14 Menactra Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 15 Menveo Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 16 Nimenrix Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 17 Bexsero Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 18 Trumenba Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 19 Meningococcal Vaccines Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 20 Hospital Pharmacies Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 21 Retail Pharmacies Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 22 Online Pharmacies Market, by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 23 Meningococcal Vaccines Market, By Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 24 North America Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 25 North America Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 26 North America Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 27 North America Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 28 U.S. Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 29 U.S. Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 30 Canada Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 31 Canada Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 32 Europe Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 33 Europe Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 34 Europe Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 35 Europe Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 36 Germany Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 37 Germany Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 38 U.K. Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 39 UK Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 40 France Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 41 France Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 42 Italy Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 43 Italy Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 44 Spain Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 45 Spain Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 46 Rest of Europe Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 47 Rest of Europe Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 48 Asia Pacific Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 49 Asia Pacific Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 50 Asia Pacific Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 51 Asia Pacific Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 52 China Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 53 China Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 54 India Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 55 India Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 56 South Korea Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 57 South Korea Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 58 Australia Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 59 Australia Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 60 Rest of Asia Pacific Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 61 Rest of Asia Pacific Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 62 Latin America Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 63 Latin America Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 64 Latin America Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 65 Latin America Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 66 Brazil Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 67 Brazil Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 68 Rest of LATAM Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 69 Rest of LATAM Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 70 MEA Meningococcal Vaccines Market, By Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 71 MEA Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 72 MEA Meningococcal Vaccines Market by Serogroups, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 73 MEA Meningococcal Vaccines Market by Distribution Channel, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 74 South Africa Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 75 South Africa Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 76 GCC Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 77 GCC Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 78 Rest of MEA Meningococcal Vaccines Market, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 79 Rest of MEA Meningococcal Vaccines Market by Type, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 80 Key Business Strategies Adopted by Key Players in Meningococcal Vaccines Market Details
Table 81 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 GSK plc: Product Benchmarking
Table 83 GSK plc: Product Pipeline
Table 84 GSK plc: Company Recent Developments
Table 85 BIO-MED: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 BIO-MED: Product Benchmarking
Table 87 Hualan Biological Bacterin Co., Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Hualan Biological Bacterin Co., Ltd: Product Benchmarking
Table 89 Incepta Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Incepta Pharmaceuticals Ltd.: Product Benchmarking
Table 91 JN International: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 JN International: Product Benchmarking
Table 93 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Pfizer Inc.: Product Benchmarking
Table 95 Pfizer Inc.: Company Recent Developments
Table 96 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Sanofi: Product Benchmarking
Table 98 Sanofi: Product Pipeline
Table 99 Sanofi: Company Recent Developments
Table 100 Serum Institute of India Pvt. Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Serum Institute of India Pvt. Ltd: Product Benchmarking
Table 102 Serum Institute of India Pvt. Ltd: Company Recent Developments
Table 103 Walvax Biotechnology Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Walvax Biotechnology Co., Ltd.: Product Benchmarking
Table 105 Walvax Biotechnology Co., Ltd.: Product Pipeline
List of Figures
Figure 1 Meningococcal Vaccines Market Segmentation
Figure 2 Meningococcal Vaccines Market Forecast by Region: Market Attractiveness Index
Figure 3 Meningococcal Vaccines Market by Type: Market Attractiveness Index
Figure 4 Meningococcal Vaccines Market by Serogroups: Market Attractiveness Index
Figure 5 Meningococcal Vaccines Market by Distribution Channel: Market Attractiveness Index
Figure 6 Meningococcal Vaccines Market: Market Dynamics
Figure 7 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): “V” Shaped Recovery
Figure 8 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): “U” Shaped Recovery
Figure 9 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): “W” Shaped Recovery
Figure 10 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %): “L” Shaped Recovery
Figure 11 Meningococcal Vaccines Market: Porter’s Five Forces Analysis
Figure 12 Meningococcal Vaccines Market: PEST Analysis
Figure 13 Meningococcal Vaccines Market Forecast by Type 2023 (Revenue, CAGR%)
Figure 14 Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 15 Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 16 Polysaccharide Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 17 Polysaccharide vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 18 Conjugate Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 19 Conjugate vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 20 Combination Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 21 Combination Vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 22 Men B Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 23 Men B vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 24 Meningococcal Vaccines Market Forecast by Serogroups 2023 (Revenue, CAGR%)
Figure 25 Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 26 Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 27 A, B, C, Y, W-135 Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 28 A, B, C, Y, W-135 vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 29 Serogroup Men B Vaccines Market Forecast by Region, 2024-2034 (US$ million)
Figure 30 Serogroup Men B Vaccines Market Share Forecast by Region, 2024-2034 (%)
Figure 31 Menactra Market Forecast, 2024-2034 (US$ million)
Figure 32 Menveo Market Forecast, 2024-2034 (US$ million)
Figure 33 Nimenrix Market Forecast, 2024-2034 (US$ million)
Figure 34 Bexsero Market Forecast, 2024-2034 (US$ million)
Figure 35 Trumenba Market Forecast, 2024-2034 (US$ million)
Figure 36 Meningococcal Vaccines Market Forecast by Distribution Channel 2023 (Revenue, CAGR%)
Figure 37 Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 38 Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 39 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 40 Hospital Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 41 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 42 Retail Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 43 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 44 Online Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 45 Meningococcal Vaccines Market Forecast by Region 2024, 2034 (Revenue)
Figure 46 Meningococcal Vaccines Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 47 Meningococcal Vaccines Market by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Figure 48 North America Meningococcal Vaccines Market Attractiveness Index
Figure 49 North America Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 50 North America Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 51 North America Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034(%)
Figure 52 North America Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 53 North America Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 54 North America Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 55 North America Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 56 North America Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 57 North America Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 58 U.S. Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 59 U.S. Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 60 U.S. Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 61 Canada Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 62 Canada Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 63 Canada Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 64 Europe Meningococcal Vaccines Market Attractiveness Index
Figure 65 Europe Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 66 Europe Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 67 Europe Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 68 Europe Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 69 Europe Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 70 Europe Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 71 Europe Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 72 Europe Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 73 Europe Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 74 Germany Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 75 Germany Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 76 Germany Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 77 UK Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 78 U.K. Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 79 U.K. Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 80 France Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 81 France Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 82 France Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 83 Italy Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 84 Italy Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 85 Italy Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 86 Spain Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 87 Spain Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 88 Spain Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 89 Rest of Europe Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 90 Rest of Europe Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 91 Rest of Europe Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 92 Asia Pacific Meningococcal Vaccines Market Attractiveness Index
Figure 93 Asia Pacific Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 94 Asia Pacific Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 95 Asia Pacific Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 96 Asia Pacific Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 97 Asia Pacific Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 98 Asia Pacific Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 99 Asia Pacific Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 100 Asia Pacific Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 101 Asia Pacific Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 102 China Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 103 China Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 104 China Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 105 India Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 106 India Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 107 India Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 108 South Korea Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 109 South Korea Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 110 South Korea Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 111 Australia Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 112 Australia Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 113 Australia Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 114 Rest of Asia Pacific Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 115 Rest of APAC Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 116 Rest of APAC Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 117 Latin America Meningococcal Vaccines Market Attractiveness Index
Figure 118 Latin America Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 119 Latin America Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 120 Latin America Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 121 Latin America Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 122 Latin America Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 123 Latin America Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 124 Latin America Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 125 Latin America Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 126 Latin America Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 127 Brazil Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 128 Brazil Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 129 Brazil Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 130 Rest of LATAM Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 131 Rest of LATAM Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 132 Rest of LATAM Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 133 MEA Meningococcal Vaccines Market Attractiveness Index
Figure 134 MEA Meningococcal Vaccines Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 135 MEA Meningococcal Vaccines Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 136 MEA Meningococcal Vaccines Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 137 MEA Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 138 MEA Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 139 MEA Meningococcal Vaccines Market Forecast by Serogroups, 2024-2034 (US$ Million, AGR %)
Figure 140 MEA Meningococcal Vaccines Market Share Forecast by Serogroups, 2024, 2029, 2034 (%)
Figure 141 MEA Meningococcal Vaccines Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 142 MEA Meningococcal Vaccines Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 143 South Africa Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 144 South Africa Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 145 South Africa Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 146 GCC Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 147 GCC Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 148 GCC Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 149 Rest of MEA Meningococcal Vaccines Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 150 Rest of MEA Meningococcal Vaccines Market Forecast by Type, 2024-2034 (US$ Million, AGR %)
Figure 151 Rest of MEA Meningococcal Vaccines Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 152 Meningococcal Vaccines Market: Company Market Share Analysis, 2022
Figure 153 GSK plc: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 154 GSK plc: Regional Market Shares, 2022
Figure 155 GSK plc: R&D, 2018-2022 (US$ Million, AGR %)
Figure 156 Pfizer Inc.: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 157 Pfizer Inc.: Regional Market Shares, 2022
Figure 158 Pfizer Inc.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 159 Sanofi: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 160 Sanofi: Regional Market Shares, 2022
Figure 161 Sanofi: R&D, 2018-2022 (US$ Million, AGR %)
ページTOPに戻る
Visiongain社の医薬・化学品分野での最新刊レポート
本レポートと同じKEY WORD（channel）の最新刊レポート
よくあるご質問
Visiongain社はどのような調査会社ですか?
英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る
調査レポートの納品までの日数はどの程度ですか?
在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。
注文の手続きはどのようになっていますか?
1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。
お支払方法の方法はどのようになっていますか?
納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。
データリソース社はどのような会社ですか?
当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。
|
|
